Agilent Technologies Inc. stock (US00846U1016): Q1 2026 earnings miss by a hair while revenue rises 7%

Agilent Technologies opened its 2026 fiscal year with slightly weaker-than-expected earnings per share but solid 7% revenue growth, as investors watch guidance and demand trends in life science and diagnostics markets.

Agilent Technologies Inc. started its 2026 fiscal year with first-quarter earnings that missed Wall Street expectations by a narrow margin, while posting mid?single?digit revenue growth and reiterating guidance for the current quarter, according to data compiled by MarketBeat as of 02/25/2026. The life science tools and diagnostics supplier remains closely watched by US investors given its New York Stock Exchange listing under the ticker A.

As of: 05/15/2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Agilent Technologies
• Sector/industry: Life science tools, diagnostics and analytical instruments
• Headquarters/country: Santa Clara, United States
• Core markets: Pharmaceutical and biopharma research, diagnostics labs, chemical and advanced materials, food and environmental testing
• Key revenue drivers: Instrument systems, consumables, and related services for laboratories
• Home exchange/listing venue: NYSE (ticker: A)
• Trading currency: US dollar (USD)

Agilent Technologies Inc.: core business model

Agilent Technologies focuses on laboratory technologies and services that help customers analyze, test, and measure chemical, biological, and physical properties of samples. The company’s portfolio spans analytical instruments, automation platforms, consumables, and software that are used by scientists and technicians in research, quality control, and diagnostics settings worldwide.

The business is typically structured around segments such as life sciences and applied markets, diagnostics and genomics, and cross?lab services, although segment naming can change over time. In life sciences and applied markets, Agilent supplies chromatography and mass spectrometry systems that are used to identify and quantify compounds in pharmaceuticals, food, and environmental samples. These systems are often sold with recurring consumables and services, creating a mix of equipment and follow?on revenue.

In diagnostics and genomics, Agilent provides reagents, instruments, and workflow solutions that support pathology labs, clinical testing, and genetic analysis. This part of the business tends to be more closely tied to healthcare and patient outcomes, including applications in oncology and companion diagnostics. The services segment supports customers through maintenance, calibration, and consulting, aiming to keep installed instruments running efficiently and within regulatory standards.

Main revenue and product drivers for Agilent Technologies Inc.

Agilent’s revenue model blends one?time instrument sales with high?margin recurring revenue from consumables, reagents, and services. Large laboratory instruments such as gas and liquid chromatographs, mass spectrometers, and spectroscopy systems can represent substantial capital purchases for customers. Once installed, these systems typically require continuous supplies of columns, standards, kits, and other consumables, alongside periodic service contracts, which smooths the company’s revenue profile over time.

On the product side, growth is often influenced by new platform launches and upgrades that improve sensitivity, throughput, or ease of use. For example, higher?performance mass spectrometry systems and automated sample?prep solutions can help laboratories handle increasing sample volumes and stricter regulatory requirements. In diagnostics, assay menus and validated workflows can be a competitive differentiator, especially when linked to specific therapeutic areas. Market commentary has noted ongoing product introductions and biopharma collaborations as drivers of sentiment around the stock, according to an analysis on Simply Wall St as of 04/22/2026.

Geographically, Agilent serves customers in North America, Europe, and Asia, with the US remaining a key market due to its concentration of pharmaceutical research, biotechnology firms, and academic labs. Demand from China and other emerging markets can also influence growth trends, especially for applied markets such as food safety and environmental testing. For US?based investors, the company’s exposure to global capital spending cycles in pharma, chemicals, and public research budgets is an important factor when considering potential earnings volatility.

Recent earnings: slight EPS miss but revenue growth

For the quarter ended in early 2026, which the company reports as its first quarter of fiscal 2026, Agilent posted earnings per share of 1.36 USD, coming in 0.01 USD below the consensus estimate of 1.37 USD, according to data compiled by MarketBeat as of 02/25/2026. While the miss was small in absolute terms, it indicates that earnings momentum is being closely calibrated by analysts after a period of strong performance in life science tools stocks.

Quarterly revenue reached about 1.80 billion USD, representing 7.0% year?over?year growth for the same reporting period, but slightly below analyst expectations near 1.81 billion USD, based on the same compilation by MarketBeat as of 02/25/2026. The modest shortfall versus estimates suggests that demand remained solid across key end markets but did not materially outperform consensus. The combination of revenue growth and a marginal EPS miss reflects both underlying expansion and ongoing cost and mix dynamics.

Over the last four reported quarters combined, Agilent generated earnings per share of 4.53 USD and annual revenue of roughly 6.95 billion USD, alongside net income of about 1.30 billion USD, according to summary figures from MarketBeat as of 02/25/2026. These numbers provide context for the company’s profitability profile: a sizable installed base and recurring revenue help support steady earnings, but margins can still shift with changes in product mix and investment in growth initiatives.

Guidance and growth expectations

Alongside its latest quarterly report, Agilent issued guidance for the second quarter of fiscal 2026. Management projected earnings per share in a range of 1.39 to 1.42 USD for the period, compared with the consensus estimate of about 1.40 USD, according to data compiled by MarketBeat as of 02/25/2026. On the revenue side, the company guided to approximately 1.8 billion USD, broadly in line with analyst expectations for the quarter.

Looking further out, aggregated forecasts point to earnings growth over the coming year. Consensus expectations compiled by MarketBeat as of 02/25/2026 indicate that Agilent’s earnings per share could rise from an estimated 5.95 USD to about 6.55 USD in the next year, implying growth of just over 10%. Such projections are inherently uncertain and depend on continued strength in biopharma and diagnostics demand, as well as the company’s ability to manage costs and deliver on new initiatives.

For investors, guidance can serve as a reference point for how management sees the near?term operating environment. In Agilent’s case, the Q2 2026 outlook suggests a continuation of mid?single?digit to high?single?digit revenue expansion, with management apparently comfortable enough with market conditions to outline earnings per share above or around current expectations. Any revisions to this guidance in future quarters could become a catalyst for the stock.

Valuation metrics and share price context

Market valuation provides another lens for assessing how the latest earnings data are being reflected in Agilent’s stock. The company recently traded around 112.80 USD per share in regular hours on the New York Stock Exchange on 05/13/2026, with a slight move to 112.87 USD in extended trading, according to closing data compiled by MarketBeat as of 05/13/2026. Separate intraday and historical data show that the stock has delivered a generally flat performance over the past year, with more positive momentum over shorter time frames.

One set of market data indicates that the shares have gained about 1.62% over the last week, are up roughly 11.12% over the past month, and show a near?flat change of 0.08% over the last year, according to price performance figures on TradingView as of 05/13/2026. This pattern suggests that sentiment may have improved recently, perhaps reflecting stabilizing expectations after prior volatility, even though the longer?term return has been modest.

On a valuation basis, Agilent’s trailing price?to?earnings ratio stood near 24.9, with a forward price?to?earnings ratio around 18.96, and a price/earnings?to?growth (PEG) ratio of about 2.38, according to summary statistics from MarketBeat as of 02/25/2026. These figures place the stock in a premium but not extreme range relative to broader equity markets, reflecting investor expectations for continued growth and relatively resilient earnings in the life science tools sector.

Why Agilent Technologies Inc. matters for US investors

For US investors, Agilent is part of a group of life science tool providers that play a crucial role in enabling pharmaceutical discovery, biotechnology innovation, and clinical diagnostics. Because the company is listed on the New York Stock Exchange and reports in US dollars, it is relatively accessible for domestic investors compared with some international peers. Its performance can serve as an indicator of broader trends in laboratory spending, including how biopharma and healthcare providers allocate budgets to research and testing infrastructure.

Additionally, the company’s revenue base is globally diversified, which can provide some balance between US and international demand. When US research funding is robust and pharmaceutical capital spending is strong, Agilent may benefit from increased orders of analytical equipment and consumables. Conversely, shifts in regulatory frameworks, changes in reimbursement for diagnostics, or slowdowns in capital budgets could weigh on orders and service contracts. For investors seeking exposure to scientific and medical innovation, Agilent sits in a supply?chain position rather than directly bearing drug development risk.

Risks and open questions

Despite steady growth trends, Agilent faces several risks that investors may monitor. Competition in analytical instruments and diagnostics is intense, with multiple global players developing comparable platforms and solutions. Pricing pressure, product differentiation, and the pace of innovation all have the potential to influence margins. Furthermore, the company’s exposure to government and academic funding means that changes in public research budgets, particularly in the US and Europe, can affect demand for its instruments and services.

Regulatory and legal developments also merit attention. For example, intellectual property disputes in the life science tools space can shape market access for specific technologies. An illustration of legal complexity in this sector is the patent case Agilent Technologies v. Synthego Corp., which has been discussed in the context of enablement standards under US patent law, according to a legal analysis on MarketScreener as of 05/14/2026. While such discussions may not directly translate into immediate financial impact, they underscore the importance of intellectual property protection for companies operating at the intersection of technology and biology.

Conclusion

Agilent Technologies entered fiscal 2026 with a quarter that delivered solid 7% revenue growth but a marginal earnings miss versus consensus, while management’s guidance and external forecasts point to continued earnings expansion over the coming year. The stock’s recent trading pattern shows modest short?term gains against a largely flat 12?month backdrop, and valuation metrics indicate that investors still ascribe a growth premium to the business. For US investors, Agilent offers exposure to laboratory infrastructure underpinning global life science and diagnostics markets, along with the usual risks tied to competition, funding cycles, and regulatory developments. As always, individual investment decisions depend on each investor’s objectives, risk tolerance, and broader portfolio context.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.